CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
ID: 355038Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $300K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355038

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-030.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed). This funding opportunity aims to support basic research projects focused on understanding the mechanisms of toxicity associated with chemical warfare agents, toxic industrial chemicals, and pesticides that impact neurological functions. The initiative is crucial for developing therapeutic countermeasures in scenarios of civilian mass exposure to chemical threats, enhancing public health safety. Eligible applicants can receive up to $300,000 per year for a maximum of three years, with applications accepted starting September 17, 2024, and a closing date of October 16, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-030.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-030-Full-Announcement.html
    PAR-24-030.html
    The NIH's Department of Health and Human Services released a Notice of Funding Opportunity (NOFO) targeting basic research on mechanisms of toxicity related to chemical threats affecting the nervous system. Specifically, this initiative seeks applications under the NIH Countermeasures Against Chemical Threats (CounterACT) program aimed at understanding how chemical warfare agents and industrial chemicals impact neurological functions. The research supported is expected to identify new pathways for therapeutic countermeasures in civilian mass exposure scenarios. Applications will be accepted starting September 17, 2024, with a maximum funding of $300,000 per year for a three-year project period, supporting up to four awards totaling $2 million. Eligibility extends to various organizations, including higher education institutions, nonprofits, and government entities. Key research topics focus on defining molecular mechanisms of toxicity, model development, and understanding long-term effects following acute exposures. The application process requires adherence to strict NIH guidelines for rigor and transparency, underlining the importance of comprehensive biosafety measures given the hazardous nature of chemical agents. This effort is integral to enhancing public health safety against chemical threats.
    Similar Opportunities
    CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT), aimed at supporting the early-stage development of therapeutics to mitigate health impacts from toxic chemical exposures. This initiative focuses on identifying and validating therapeutic candidates that can address the effects of chemical warfare agents and toxic industrial chemicals, particularly in large-scale public health emergencies. Eligible applicants, including higher education institutions, nonprofits, and tribal governments, can request funding up to $350,000 annually for the UG3 phase and $450,000 for the UH3 phase, with applications due by October 17, 2024. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms," aimed at supporting research into the mechanisms of chemical toxicity affecting the lungs and eyes. This initiative seeks to fund projects that explore the health impacts of chemical threat agents, with a focus on identifying molecular and genetic targets for therapeutic countermeasures, utilizing various research methodologies such as animal models and computational modeling. A total of approximately $3 million is available to support up to five grants, with each project eligible for a maximum budget of $300,000 per year over a three-year period. Interested applicants should note that the application period opens on August 24, 2024, with a final submission deadline of September 24, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Chemical Countermeasures Research Program (CCRP) to support basic research on the deleterious effects of acute exposure to ultra-potent synthetic (UPS) opioids. This initiative aims to identify and validate mechanisms, signaling pathways, and therapeutic targets to understand and mitigate the toxic effects and long-term health consequences associated with UPS opioid overdoses, particularly focusing on respiratory depression and related complications. With a total funding allocation of $2.5 million for fiscal year 2023, the NIH plans to fund up to six applications, emphasizing innovative collaborative research approaches to address critical public health challenges posed by synthetic opioids. Interested applicants must submit their proposals by November 19, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at promoting research on skin injuries caused by chemical threats, as part of the Chemical Countermeasures Research Program (CCRP). This initiative, led by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), seeks to investigate the commonalities of such injuries and identify potential therapeutic targets for medical countermeasure development. The NOFO is expected to be published in Fall 2024, with applications due in Winter/Spring 2025, and will offer a funding ceiling of $450,000. Interested applicants should prepare to submit their proposals by the estimated close date of February 16, 2025, with awards anticipated to be made by December 1, 2025.
    Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)" aimed at supporting research into novel small molecules that can modulate biological targets relevant to mental health, aging, drug abuse, and eye diseases. The initiative seeks to stimulate the discovery and development of in vivo chemical probes, requiring applicants to have validated starting compounds for optimization and bioassays to test new analogs. This funding is crucial for advancing the understanding of brain disease mechanisms and emphasizes projects that provide insights into significant biological processes. Interested applicants can submit proposals until January 7, 2027, with no budget limit specified, although actual needs must be indicated. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIH Grants.
    ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment," aimed at investigating the impact of environmental risk factors (ERFs) on Alzheimer's Disease-Related Dementia (ADRD). This initiative seeks to explore how exogenous ERFs, such as toxins and pathogens, influence ADRD mechanisms at innervated human surfaces, including the gut, lungs, and skin, while explicitly prohibiting clinical trials. The NIH plans to allocate up to $3.75 million annually for this initiative, with individual project budgets capped at $500,000 over a maximum duration of five years. Applications are due by October 6, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant aimed at advancing drug discovery for nervous system disorders. This initiative focuses on the identification, design, synthesis, and preclinical testing of novel therapeutic compounds, particularly emphasizing innovative approaches to drug metabolism and pharmacokinetics, while excluding clinical trial applications. The program encourages high-risk, novel projects that aim to translate scientific research into effective treatments for conditions such as mental illness and substance use disorders. Interested applicants can find more information and guidelines in the NIH Grant Application Guide, with applications due by January 7, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)" aimed at supporting innovative research in the identification and development of novel compounds for the prevention and treatment of nervous system disorders. This initiative encourages applications focused on early-stage research, particularly in the areas of small molecules, biotechnology products, and biologics, with an emphasis on projects that utilize machine learning and propose preclinical evaluations of candidate drugs. The funding amount available is up to $275,000, with a submission deadline of January 7, 2025. Interested applicants can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.